Cambridge BRC

01. Cancer - Key Publications

  1. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate. Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF. Multiple loci on 8q24 associated with prostate cancer susceptibility; Nat Genet; 41(10):1058-60, 2009.
  2. Bartlett JMS, Munro AF, Dunn JA, McConkey Jordan CS, Twelves CJ, Cameron DA, Thomas Campbell JF, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, and Poole CJ. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncology 11: 266-274, 2010.
  3. Beer PA, Delhommeau F, LeCou'dic JP, Dawson MA, Chen E, Bareford D, Ku'ec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood; 115(14): 2891-2900, 2010.
  4. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol; 27: 2991-2999, 2009.
  5. Dawson MA', Bannister AJ', Gottgens B, Foster SD, Bartke T, Green AR*, Kouzarides T* (*joint senior authors; 'joint first author). JAK2 phosphorylates histone H3Y41 and excludes HP1a from chromatin. Nature; 461(7265): 819-822, 2009.
  6. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, Le Quesne J, Greenberg DC, Pharoah P, Caldas C, and Wishart GC. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. British Journal of Cancer; 101: 1338-1344, 2009.
  7. Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC. Non-endoscopic screening test for Barrett's oesophagus: acceptability and accuracy in a primary care setting. BMJ;341:c4372, 2010.
  8. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci; 107:2177-82, 2010.
  9. Thirkettle HJ, Mills IG, Whitaker HC, Neal DE. Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene; 28(41):3663-70, 2009.
  10. Wishart GC, Azzato E, Greenberg D, Rashbass J, Kearins O, Lawrence G, Caldas C, and Pharoah P. PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Research; 12: R1, 2010
PageBanners: 
Rightnav: 
Highlights Urological Cancer: David Neal Funding from the BRC has been used to develop and support the biorepository and to ensure optimum collection of tissue for translational research into prostate cancer. Read more...